Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPRX Catalyst Pharmaceuticals	$22.12 -1.6%	$23.93	$14.75 ▼ $26.58	$2.74B	0.72	1.10 million shs	1.30 million shs
MRUS Merus	$52.74 -0.7%	$48.03	$33.19 ▼ $62.98	$3.68B	1.04	756,305 shs	748,995 shs
PHVS Pharvaris	$17.42 -3.2%	$16.51	$11.51 ▼ $25.50	$940.70M	-2.86	71,695 shs	22,188 shs
PTGX Protagonist Therapeutics	$53.36 +0.0%	$48.10	$30.67 ▼ $60.60	$3.31B	2.25	896,700 shs	549,742 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPRX Catalyst Pharmaceuticals	0.00%	-4.46%	-8.21%	-12.67%	+44.19%
MRUS Merus	0.00%	-2.77%	-3.70%	+8.88%	-3.17%
PHVS Pharvaris	0.00%	+7.72%	+12.51%	+16.29%	-5.56%
PTGX Protagonist Therapeutics	0.00%	-5.38%	+16.82%	+1.54%	+65.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CPRX Catalyst Pharmaceuticals	4.9256 of 5 stars	3.6	2.0	3.9	3.4	3.3	3.8
MRUS Merus	3.145 of 5 stars	4.6	3.0	0.0	2.1	1.7	0.0
PHVS Pharvaris	1.3824 of 5 stars	3.5	1.0	0.0	1.3	0.0	0.0
PTGX Protagonist Therapeutics	1.3329 of 5 stars	2.5	2.0	0.0	2.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPRX Catalyst Pharmaceuticals	3.25	Buy	$32.83	48.43% Upside
MRUS Merus	3.14	Buy	$84.64	60.48% Upside
PHVS Pharvaris	3.00	Buy	$36.20	107.81% Upside
PTGX Protagonist Therapeutics	3.00	Buy	$66.10	23.88% Upside

Current Analyst Ratings Breakdown

Latest PHVS, PTGX, CPRX, and MRUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$72.00
6/11/2025	PHVS Pharvaris	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$32.00
6/5/2025	CPRX Catalyst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/5/2025	PHVS Pharvaris	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$27.00
6/3/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
5/23/2025	MRUS Merus	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
5/19/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
5/19/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/14/2025	PHVS Pharvaris	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$28.00 ➝ $25.00
5/8/2025	MRUS Merus	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$91.00 ➝ $89.00
4/29/2025	PHVS Pharvaris	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$28.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPRX Catalyst Pharmaceuticals	$491.73M	5.49	$2.41 per share	9.19	$6.10 per share	3.63
MRUS Merus	$36.13M	101.03	N/A	N/A	$9.46 per share	5.58
PHVS Pharvaris	N/A	N/A	N/A	N/A	$5.54 per share	N/A
PTGX Protagonist Therapeutics	$434.43M	7.61	$4.52 per share	11.81	$11.33 per share	4.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPRX Catalyst Pharmaceuticals	$163.89M	$1.57	14.09	10.38	0.92	36.91%	42.45%	36.59%	8/6/2025 (Estimated)
MRUS Merus	-$215.33M	-$4.08	N/A	N/A	N/A	-506.73%	-35.99%	-29.83%	7/30/2025 (Estimated)
PHVS Pharvaris	-$145.24M	-$3.01	N/A	N/A	N/A	N/A	-54.02%	-50.36%	8/13/2025 (Estimated)
PTGX Protagonist Therapeutics	$275.19M	$0.75	71.15	N/A	N/A	27.04%	9.22%	8.31%	8/5/2025 (Estimated)

Latest PHVS, PTGX, CPRX, and MRUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/13/2025	Q1 2025	PHVS Pharvaris	-$0.80	-$0.89	-$0.09	-$0.89	N/A	N/A
5/6/2025	Q1 2025	PTGX Protagonist Therapeutics	-$0.50	-$0.19	+$0.31	-$0.19	$30.44 million	$28.32 million
4/7/2025	Q4 2024	PHVS Pharvaris	-$0.74	-$0.68	+$0.06	-$0.68	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPRX Catalyst Pharmaceuticals	N/A	6.14	5.96
MRUS Merus	N/A	5.86	5.86
PHVS Pharvaris	N/A	11.10	11.10
PTGX Protagonist Therapeutics	N/A	17.25	17.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPRX Catalyst Pharmaceuticals	79.22%
MRUS Merus	96.14%
PHVS Pharvaris	N/A
PTGX Protagonist Therapeutics	98.63%

Insider Ownership

Company	Insider Ownership
CPRX Catalyst Pharmaceuticals	10.40%
MRUS Merus	4.57%
PHVS Pharvaris	N/A
PTGX Protagonist Therapeutics	4.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPRX Catalyst Pharmaceuticals	80	121.97 million	109.29 million	Optionable
MRUS Merus	37	69.21 million	66.05 million	Optionable
PHVS Pharvaris	30	52.29 million	N/A	Not Optionable
PTGX Protagonist Therapeutics	120	61.98 million	58.95 million	Optionable

PHVS, PTGX, CPRX, and MRUS Headlines

Recent News About These Companies

Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth

June 20 at 6:40 PM | investing.com

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity

June 20 at 1:39 PM | msn.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Position Lifted by Exchange Traded Concepts LLC

June 19, 2025 | marketbeat.com

Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated at Citigroup

June 19, 2025 | americanbankingnews.com

Protagonist Therapeutics (NASDAQ:PTGX) Now Covered by Citigroup

June 17, 2025 | marketbeat.com

Assenagon Asset Management S.A. Sells 7,367 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

June 17, 2025 | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $65.44 Average Target Price from Analysts

June 17, 2025 | americanbankingnews.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Buy" from Brokerages

June 14, 2025 | marketbeat.com

GAMMA Investing LLC Raises Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

June 13, 2025 | marketbeat.com

Arturo Md Molina Sells 10,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock

June 12, 2025 | insidertrades.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Insider Arturo Md Molina Sells 10,000 Shares

June 11, 2025 | marketbeat.com

Protagonist Therapeutics (NASDAQ:PTGX) Upgraded to "Hold" at Wall Street Zen

June 8, 2025 | marketbeat.com

Hennion & Walsh Asset Management Inc. Sells 6,008 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

June 7, 2025 | marketbeat.com

Short Interest in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Decreases By 13.6%

June 5, 2025 | marketbeat.com

9 Analysts Assess Protagonist Therapeutics: What You Need To Know

June 4, 2025 | benzinga.com

Protagonist Therapeutics' (PTGX) "Buy" Rating Reaffirmed at HC Wainwright

June 3, 2025 | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stake Lifted by Mackenzie Financial Corp

June 2, 2025 | marketbeat.com

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

June 1, 2025 | businesswire.com

Wellington Management Group LLP Boosts Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

June 1, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $11.11 Million Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

June 1, 2025 | marketbeat.com

Nuveen Asset Management LLC Sells 80,877 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

June 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHVS, PTGX, CPRX, and MRUS Company Descriptions

Catalyst Pharmaceuticals NASDAQ:CPRX

$22.12 -0.36 (-1.60%)

Closing price 04:00 PM Eastern

Extended Trading

$22.44 +0.32 (+1.45%)

As of 07:55 PM Eastern

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Merus NASDAQ:MRUS

$52.74 -0.36 (-0.68%)

Closing price 04:00 PM Eastern

Extended Trading

$52.74 0.00 (0.00%)

As of 07:36 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Pharvaris NASDAQ:PHVS

$17.42 -0.57 (-3.17%)

Closing price 04:00 PM Eastern

Extended Trading

$17.44 +0.02 (+0.14%)

As of 05:17 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Protagonist Therapeutics NASDAQ:PTGX

$53.36 +0.02 (+0.04%)

Closing price 04:00 PM Eastern

Extended Trading

$53.32 -0.03 (-0.07%)

As of 05:51 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time